Clinical trials
Immunogenicity clinical trials
Below are recruiting immunogenicity clinical trials, each written for real people, not researchers. We’re tracking 146 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07304284RecruitingPhase 3
Cholera vaccine study for healthy adults and people with HIV
This trial tests a new cholera vaccine (Biovac OCV-S) to see if it works as well as the current vaccine (Euvichol-Plus). It is for healthy people aged 1 to 45, and also for adults with HIV who are on treatment.
Durban, Eastern CapeAges 1–45 - NCT07287982RecruitingPhase 2
ARGX-119 for children with SMA who can walk
This study tests a new medicine called ARGX-119 in children with SMA. It is given through an IV and aims to help kids who can already walk get stronger and stay healthy.
Little Rock, ArkansasAges 5–17 - NCT06126822RecruitingPhase 3
Study of Ebola vaccine booster in previously vaccinated adults
This study tests if a booster dose of one of two Ebola vaccines (Ervebo® or Zabdeno®) is safe and works well in people who already got an Ebola vaccine more than 4 months ago. It's especially for people living in the Democratic Republic of Congo (DRC) who may have been vaccinated before and might need a stronger, longer-lasting immune response.
GomaAges 18–50 - NCT06608199RecruitingPhase 3
Pneumonia vaccine study for healthy infants
This study tests a new pneumonia vaccine (PCV13) in healthy infants to see if it works as well as a current vaccine. It compares the immune response and safety of the two vaccines.
Denpasar, BaliAges 1 month–2 months - NCT07258745RecruitingPhase 1
Comparing a risankizumab biosimilar to Skyrizi in healthy adults
This study tests a new biosimilar medicine (CKD-704) to see how it compares to the approved Skyrizi treatments for healthy adults. It checks how the medicine moves through the body, its safety, and how the immune system responds.
Warsaw, WarszawaAges 18–55 - NCT07252804RecruitingPhase 4
Testing the MenB vaccine safety and immune response in children with rheumatic disease
This trial tests a meningitis B vaccine (MenB-4C) in children and young adults with autoimmune rheumatic diseases. It aims to see if the vaccine is safe and works well for these patients.
São Paulo, São PauloAges 2–25 - NCT07252791RecruitingPhase 4
PCV20 vaccine study for kids and young adults with rheumatic diseases
This study tests if a pneumonia vaccine (PCV20) is safe and works well in children and young adults with certain autoimmune rheumatic diseases like juvenile arthritis, lupus, or dermatomyositis. It aims to help protect them from serious infections.
São Paulo, São PauloAges 2–25 - NCT06874842RecruitingPhase 1
Testing a new shingles vaccine in adults 40 and older
This trial tests a new shingles vaccine (LYB004) in adults 40 and older. It looks at how safe the vaccine is and how well it helps your body build protection against shingles.
MeizhouAges 40 years+ - NCT07242092RecruitingPhase 4
Pausing methotrexate to boost pneumonia vaccine response
This study tests whether stopping methotrexate for a short time before getting the pneumonia vaccine (PCV20) helps your body build a stronger immune response. It is for people with autoimmune rheumatic diseases like rheumatoid arthritis or lupus whose disease is under control.
São Paulo, São PauloAges 18–100 - NCT07237464RecruitingPhase 1
Safety study of GB18 injection in healthy adults
This early-phase trial tests a new injection called GB18 in healthy adults to see if it is safe and how the body processes it. It may help researchers understand how to treat conditions that involve the immune system.
Beijing, Beijing MunicipalityAges 18–55 - NCT07221734RecruitingPhase 3
Testing MB11 versus Opdivo for advanced melanoma
This trial compares a new drug, MB11, to the standard treatment Opdivo for people with advanced melanoma that hasn't been treated yet. The goal is to see if MB11 works just as well.
FunchalAges 18 years+ - NCT07213830RecruitingPhase 1/Phase 2
Study of IPN01203 for advanced solid tumors after immunotherapy
This trial tests an experimental drug called IPN01203 for people with advanced solid tumors that have grown after prior immunotherapy. The goal is to see if the drug is safe and can shrink tumors.
Grand Rapids, MichiganAges 18 years+ - NCT07213817RecruitingPhase 1/Phase 2
Safety and effectiveness of IPN60300 for advanced solid tumors
This trial tests a new drug called IPN60300 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink tumors.
New Haven, ConnecticutAges 18 years+ - NCT07205926RecruitingPhase 1
Testing a new Shigella vaccine in healthy adults
This trial tests a new Shigella vaccine in healthy adults to see if it is safe and creates a good immune response. It is a first-in-human study, meaning this is the first time the vaccine is given to people.
Cincinnati, OhioAges 18–49 - NCT07204457RecruitingPhase 2/Phase 3
Meningococcal vaccine trial for healthy adults 19 to 55 years old
This trial tests a new meningococcal conjugate vaccine (EG-MCV4) in healthy adults to see how well the body's immune system responds and if it's safe. If you qualify, you'd help researchers learn if this vaccine can prevent meningococcal disease.
SeoulAges 19–55 - NCT05266898RecruitingPhase 4
HPV vaccine response study for people living with HIV
This trial studies how well the Gardasil-9 HPV vaccine triggers the body’s immune response in people living with HIV. It may help doctors understand the best way to protect against HPV-related cancers and infections in this population.
New Orleans, LouisianaAges 18–65 - NCT07199270RecruitingPhase 1
Safety study of GR2303 in healthy adults
This trial tests a new drug called GR2303 to see if it is safe and how the body processes it. It is for healthy adults who have not used similar drugs before.
Beijing, Beijing MunicipalityAges 18–45 - NCT06255626RecruitingPhase 1/Phase 2
New COVID-19 booster vaccine study
This trial tests a new type of COVID-19 booster vaccine that targets a protein to help your immune system. It's for people who already had a primary vaccine series and at least one mRNA booster, with the last booster at least 6 months ago.
CréteilAges 18–84 - NCT06306196RecruitingPhase 2
Hepatitis E vaccine study in healthy adults, children, and people with HIV
This study tests a hepatitis E vaccine called Hecolin in healthy people (ages 2–45) and in adults (18–45) living with HIV who are on antiviral treatment. It aims to see how well the vaccine works and if it's safe for different groups.
Ga-RankuwaAges 2–45 - NCT07176650RecruitingPhase 1
Testing a biosimilar ipilimumab for advanced liver cancer
This trial tests a new version of the immunotherapy drug ipilimumab (called HLX13) against the approved version (YERVOY) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if the new version works similarly and is as safe.
Glendale, CaliforniaAges 18–65 - NCT07136389RecruitingPhase 1
Testing 2 drugs for active lupus skin disease
This trial tests two new drugs, BCD-256-1 and divozilimab, for people with systemic lupus erythematosus (SLE) who have active skin symptoms not controlled by current treatments. The goal is to see if they are safe and how the body processes them.
Saint PetersburgAges 18–70 - NCT07121413RecruitingPhase 2
Testing SV001 for Idiopathic Pulmonary Fibrosis
This trial tests a new drug called SV001 to see if it is safe and tolerable for people with idiopathic pulmonary fibrosis (IPF). If you have IPF and meet certain health criteria, this study may help find new treatment options.
ChengduAges 40 years+ - NCT07120464Recruiting
Rabies vaccine study for people with weak immune systems or older age
This study tests how well a rabies vaccine works and how safe it is for people whose immune systems may be weaker, such as those with certain long-term illnesses, organ transplants, or age 60 and older. It compares them to healthy adults ages 18 to 59.
Shenzhen, GuangdongAges Any age - NCT06752746RecruitingPhase 1
Testing 9MW3011 for polycythemia vera in resistant patients
This trial tests a new drug called 9MW3011 for people with polycythemia vera (PV) who haven't done well on or can't take standard treatments like hydroxyurea or interferon. The goal is to see if the drug is safe and how it works in your body.
Zhengzhou, HenanAges 18 years+
Hear when a new Immunogenicity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immunogenicity?
- Yes. Clin2 currently lists 146 recruiting immunogenicity studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immunogenicity trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immunogenicity trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.